Clearmind Medicine Reports Positive Results For Intranasal MEAI Formulation In Alcohol Use Disorder Program

Clearmind Medicine Inc., a clinical-stage biotechnology company developing non-hallucinogenic neuroplastogen-based therapies for Alcohol Use Disorder (AUD), addiction, and weight management, has announced encouraging results from an ex vivo study evaluating its intranasal formulation of MEAI (5-Methoxy-2-aminoindane). The findings showed that the company's nasal formulation remained in contact with nasal tissue significantly longer than a standard MEAI solution, supporting its potential to improve drug delivery and therapeutic effectiveness.

The study is part of Clearmind's broader development program aimed at creating an intranasal version of MEAI for the treatment of Alcohol Use Disorder. One of the primary goals of the program is to increase the amount of time the drug remains inside the nasal cavity before it is naturally cleared by the body's mucociliary system. Longer nasal residence time is expected to improve drug absorption and provide more consistent dosing, which could ultimately enhance treatment outcomes.

To evaluate the formulation, researchers conducted an ex vivo mucoadhesion study using freshly isolated rabbit nasal tissue. Both the intranasal MEAI formulation and a conventional non-mucoadhesive MEAI solution were applied to the tissue surface before being exposed to a simulated nasal electrolyte solution. The amount of each formulation that remained attached to the tissue was measured over a 30-minute period, allowing researchers to compare their retention profiles.

The results showed that Clearmind's intranasal MEAI formulation consistently retained a greater proportion of the applied dose throughout the entire testing period compared with the standard MEAI solution. The improved performance is attributed to the formulation's mucoadhesive polymer system, which helps the drug remain attached to the nasal mucosa for a longer duration. These findings further validate the company's proprietary nasal drug-delivery platform, which is designed to improve drug retention and enhance overall delivery efficiency.

According to Clearmind, prolonged contact between the drug and the nasal lining is an important factor in successful intranasal therapy because it provides a greater opportunity for the medication to be absorbed before being cleared from the nasal cavity. The company believes the encouraging retention profile observed in the study suggests that its intranasal MEAI formulation could offer significant advantages over traditional non-mucoadhesive formulations.

The positive findings represent another step forward in Clearmind's efforts to develop differentiated therapies for Alcohol Use Disorder and other conditions with significant unmet medical needs. By improving nasal drug delivery and absorption, the company aims to maximize the therapeutic potential of MEAI while advancing innovative treatment options for patients affected by addiction and related disorders.